Brief: EQL Pharma Reports Q3 Sales Up 29% Y/Y
03/02/2026 11:41
Feb 3 (Reuters) - EQL Pharma AB EQL.ST: Q3 SALES RISE 29% Y/Y TO SEK 118.9 MILLION Q3 OPERATING PROFIT UP 32% Y/Y TO SEK 19.5 MILLION CASH AND CASH EQUIVALENTS AT SEK 72.7 MILLION AT END OF QUARTER CAPEX WAS SEK 11.9 (11.8) MILLION DURING QUARTER FOR FULL YEAR 2025/26, SALES GROWTH IS FORECAST AT ABOUT 15% SOME SCRAPPING OF, AMONG OTHER THINGS, COVID-19 TESTS IS EXPECTED TO NEGATIVELY AFFECT Q4 BY THREE TO FOUR PERCENTAGE POINTS EBITDA MARGIN OF 21% DOES NOT REACH INITIAL GOAL IN NEW FIVE-YEAR PLAN, TO STABILIZE EBITDA AT 25% DURING FIRST HALF OF PERIOD Source text: ID:nWkr1tQgTY Further company coverage: EQL.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))